

CITATION REPORT

List of articles citing

Results from different patient populations using combined therapy with alprostadil and sildenafil: predictors of satisfaction

DOI: 10.1046/j.1464-410x.2000.00790.x
BJU International, 2000, 86, 469-73.

Source: <https://exaly.com/paper-pdf/31325709/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
37	Modern pharmacotherapy for erectile dysfunction: evolving concepts with central and peripheral acting agents. <i>Current Opinion in Urology</i> , 2001 , 11, 625-30	2.8	2
36	Pharmacological aspects of erectile dysfunction. <i>The Japanese Journal of Pharmacology</i> , 2002 , 89, 101-12		14
35	Combination therapy for erectile dysfunction: where we are and what[is in the future. <i>Current Urology Reports</i> , 2002 , 3, 467-70	2.9	11
34	[Drug therapy of erectile dysfunction--the current status]. <i>Der Urologe</i> , 2003 , 42, 1322-9		2
33	Pharmacological management of erectile dysfunction. <i>BJU International</i> , 2003 , 91, 446-54	5.6	74
32	Viability and safety of combination drug therapies for erectile dysfunction. <i>Journal of Urology</i> , 2003 , 170, S20-3; discussion S23	2.5	23
31	Future options for combination therapy in the management of erectile dysfunction in older men. <i>Drugs and Aging</i> , 2004 , 21, 555-64	4.7	26
30	Use of combined intracorporal injection and a phosphodiesterase-5 inhibitor therapy for men with a suboptimal response to sildenafil and/or vardenafil monotherapy after radical retropubic prostatectomy. <i>BJU International</i> , 2005 , 95, 843-6	5.6	46
29	Combining programmed intracavernous PGE1 injections and sildenafil on demand to salvage sildenafil nonresponders. <i>International Journal of Impotence Research</i> , 2005 , 17, 354-8	2.3	20
28	Chapter 1: The management of erectile dysfunction: an AUA update. <i>Journal of Urology</i> , 2005 , 174, 230-9	2.5	255
27	Combination pharmacotherapy in the management of patients with hard-to-treat erectile dysfunction. <i>Journal of Sexual Medicine</i> , 2006 , 3, 185-7	1.1	1
26	Salvage strategies for nonresponders to phosphodiesterase-5 inhibitor treatment for erectile dysfunction in the aging male. <i>Aging Health</i> , 2007 , 3, 527-542		1
25	Pharmacological therapy for the treatment of sexual dysfunction--are we there yet?. <i>Journal of Urology</i> , 2008 , 179, 819-20	2.5	3
24	Toward a new [EPOCH]: optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction. <i>International Journal of Clinical Practice</i> , 2009 , 63, 1214-30	2.9	17
23	Intraurethral alprostadil for erectile dysfunction: a review of the literature. <i>Drugs</i> , 2012 , 72, 2243-54	12.1	38
22	Modern utilization of penile prosthesis surgery: a national claim registry analysis. <i>International Journal of Impotence Research</i> , 2014 , 26, 167-71	2.3	18
21	Prediction model for penile prosthesis implantation for erectile dysfunction management. <i>Current Medical Research and Opinion</i> , 2014 , 30, 2131-7	2.5	4

20	The role of intraurethral alprostadil as a first-choice erectile dysfunction treatment option in special populations: a proposed treatment algorithm. <i>Clinical Practice (London, England)</i> , 2014 , 11, 17-26 ³		2
19	Penile rehabilitation: the evolutionary concept in the management of erectile dysfunction. <i>Current Urology Reports</i> , 2014 , 15, 393	2.9	17
18	Intraurethral alprostadil in the management of erectile dysfunction: a reappraisal of the clinical evidence. <i>Clinical Practice (London, England)</i> , 2014 , 11, 3-15	3	1
17	Safety and efficacy of intraurethral alprostadil in patients with erectile dysfunction refractory to treatment using phosphodiesterase-5 inhibitors. <i>Actas Urológicas Españolas (English Edition)</i> , 2015 , 39, 635-640	0.1	
16	Safety and efficacy of intraurethral alprostadil in patients with erectile dysfunction refractory to treatment using phosphodiesterase-5 inhibitors. <i>Actas Urológicas Españolas</i> , 2015 , 39, 635-40	0.7	9
15	Satisfaction with Therapy Among Patients with Chronic Noncancer Pain with Opioid-Induced Constipation. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2016 , 22, 246-53	1.9	15
14	Current role of local treatments for erectile dysfunction in the real-life setting. <i>Current Opinion in Urology</i> , 2016 , 26, 123-8	2.8	1
13	Erectile dysfunction and infertility. 2016 , 152-171		1
12	[Side effects of erectile dysfunction drug treatment]. <i>Der Urologe</i> , 2017 , 56, 451-455		2
11	Non-invasive Management Options for Erectile Dysfunction When a Phosphodiesterase Type 5 Inhibitor Fails. <i>Drugs and Aging</i> , 2018 , 35, 175-187	4.7	12
10	Additional non-invasive options can be considered for erectile dysfunction when phosphodiesterase type 5 inhibitors fail. <i>Drugs and Therapy Perspectives</i> , 2018 , 34, 567-571	1.5	
9	Inflatable Penile Prosthesis Implantation in the Ambulatory Setting: A Systematic Review. <i>Sexual Medicine Reviews</i> , 2020 , 8, 338-347	5.6	4
8	Inflatable Penile Prosthesis in the Ambulatory Surgical Setting: Outcomes From a Large Urological Group Practice. <i>Journal of Sexual Medicine</i> , 2020 , 17, 1025-1032	1.1	4
7	Combination therapy for erectile dysfunction: an update review. <i>Asian Journal of Andrology</i> , 2011 , 13, 382-90	2.8	24
6	Erectile Dysfunction. 2005 , 193-223		
5	Erectile Dysfunction and Infertility. 2014 , 89-117		
4	Erectile Dysfunction. 2015 , 65-116		
3	Penile Rehabilitation After Prostate Cancer Treatments. 2016 , 277-288		

2 Acute Toxicities of Therapy: Urologic Complications. **2006**, 1435-1442

1 Oral and non-oral combination therapy for erectile dysfunction. *Reviews in Urology*, **2007**, 9, 99-105 1 7